Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133120 | 0.92 | PTPN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7125731 | 0.90 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7127460 | 0.87 | HPGD (0.46) | PTPN1MAPTPOLBHPGDNPSR1 | |
| SCHEMBL7134342 | 0.87 | PTPN7 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7133124 | 0.84 | PTPN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7128131 | 0.83 | CA1 (0.50) | — | |
| SCHEMBL7123575 | 0.82 | DDB1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7128728 | 0.81 | ACLY (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7127164 | 0.81 | HSD11B1 (0.42) | LMNAPOLB | |
| SCHEMBL7123146 | 0.80 | PPARD (0.45) | LMNAF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | claimed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| US-6555555-B1 | Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | disclosed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | PSEN1 400/4885PSEN2 1229/4885APH1B 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.